Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) EBITDA (2023 - 2026)

Camp4 Therapeutics' EBITDA history spans 3 years, with the latest figure at -$40.3 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 203.37% to -$40.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$80.4 million, a 55.25% decrease, with the full-year FY2025 number at -$80.4 million, down 55.25% from a year prior.
  • EBITDA hit -$40.3 million in Q4 2025 for Camp4 Therapeutics, down from -$15.1 million in the prior quarter.
  • Over the last five years, EBITDA for CAMP hit a ceiling of -$11.7 million in Q3 2023 and a floor of -$40.3 million in Q4 2025.
  • Historically, EBITDA has averaged -$15.7 million across 3 years, with a median of -$12.8 million in 2023.
  • The widest YoY moves for EBITDA: up 0.15% in 2025, down 203.37% in 2025.
  • Tracing CAMP's EBITDA over 3 years: stood at -$13.0 million in 2023, then decreased by 2.22% to -$13.3 million in 2024, then tumbled by 203.37% to -$40.3 million in 2025.
  • Business Quant data shows EBITDA for CAMP at -$40.3 million in Q4 2025, -$15.1 million in Q3 2025, and -$12.6 million in Q2 2025.